Literature DB >> 24579978

High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.

Marta Lionetti1, Sonia Fabris, Giovanna Cutrona, Luca Agnelli, Carmela Ciardullo, Serena Matis, Gabriella Ciceri, Monica Colombo, Francesco Maura, Laura Mosca, Massimo Gentile, Anna G Recchia, Fiorella Ilariucci, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzi, Davide Rossi, Gianluca Gaidano, Fortunato Morabito, Manlio Ferrarini, Antonino Neri.   

Abstract

NOTCH1 mutations have recently emerged as new genetic lesions significantly correlated with survival in chronic lymphocytic leukaemia (CLL). We performed deep next generation sequencing of the NOTCH1 mutation hotspot in 384 cases at diagnosis, including 100 monoclonal B cell lymphocytosis (MBL) and 284 Binet stage A CLL cases, enrolled in the Gruppo Italiano Studio Linfomi O-CLL1 multicentre trial. The NOTCH1 c.7541_7542delCT dinucleotide deletion was detected and confirmed by an extremely sensitive polymerase chain reaction-based approach in 11% of MBL and 13·4% of CLL patients. Remarkably, the NOTCH1 mutation was often observed at low clonal level, mainly in MBL patients. Sequential analyses in a fraction of cases showed that the NOTCH1 mutation generally does not occur during the disease course and that the mutational load in positive cases tends to be stable over time. NOTCH1-mutated cases, even at low clonal level, displayed a significant reduction in median progression-free survival, although NOTCH1 mutation lost its prognostic impact in a multivariate analysis including 11q and/or 17p deletion, IGHV mutational status, and MBL or CLL status. Our data highlight the importance of using highly sensitive methods to measure NOTCH1 mutations, in order to improve prognostic stratification and obtain useful information for potential therapeutic approaches.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  NOTCH1; chronic lymphocytic leukaemia; monoclonal B-cell lymphocytosis; next generation sequencing; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24579978     DOI: 10.1111/bjh.12800

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

Review 1.  The molecular pathogenesis of chronic lymphocytic leukaemia.

Authors:  Giulia Fabbri; Riccardo Dalla-Favera
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Authors:  Paolo Strati; Tait D Shanafelt
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 3.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

4.  Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.

Authors:  Geffen Kleinstern; Daniel R O'Brien; Xing Li; Shulan Tian; Brian F Kabat; Kari G Rabe; Aaron D Norman; Huihuang Yan; Celine M Vachon; Nicholas J Boddicker; Timothy G Call; Sameer A Parikh; Laura Bruins; Cecilia Bonolo de Campos; Jose F Leis; Tait D Shanafelt; Wei Ding; James R Cerhan; Neil E Kay; Susan L Slager; Esteban Braggio
Journal:  Am J Hematol       Date:  2020-05-07       Impact factor: 10.047

Review 5.  The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.

Authors:  Gianluca Gaidano; Davide Rossi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Authors:  G Cutrona; S Matis; M Colombo; C Massucco; G Baio; F Valdora; L Emionite; S Fabris; A G Recchia; M Gentile; C E Neumaier; D Reverberi; R Massara; S Boccardo; L Basso; S Salvi; F Rosa; M Cilli; S Zupo; M Truini; P Tassone; M Calabrese; M Negrini; A Neri; F Morabito; F Fais; M Ferrarini
Journal:  Leukemia       Date:  2017-01-05       Impact factor: 11.528

7.  The Predominant Prognostic Significance of NOTCH1 Mutation Defined by Emulsion PCR in Chronic Lymphocytic Leukemia.

Authors:  Katarzyna Skórka; Michał Chojnacki; Marta Masternak; Agnieszka Karczmarczyk; Edyta Subocz; Ewa Wawrzyniak; Krzysztof Giannopoulos
Journal:  Cancer Manag Res       Date:  2021-05-06       Impact factor: 3.989

8.  Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.

Authors:  Francesco Maura; Laura Mosca; Sonia Fabris; Giovanna Cutrona; Serena Matis; Marta Lionetti; Luca Agnelli; Marzia Barbieri; Marianna D'Anca; Martina Manzoni; Monica Colombo; Carlotta Massucco; Daniele Reverberi; Massimo Gentile; Anna Grazia Recchia; Sabrina Bossio; Fiorella Ilariucci; Caterina Musolino; Francesco Di Raimondo; Agostino Cortelezzi; Fortunato Morabito; Manlio Ferrarini; Antonino Neri
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 9.  New insights into monoclonal B-cell lymphocytosis.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Sotirios Sachanas; Theodoros P Vassilakopoulos; Stavroula Kyriakaki; Penelope Korkolopoulou; Efstathios Koulieris; Maria Moschogiannis; Xanthi Yiakoumis; Pantelis Tsirkinidis; Marie-Christine Kyrtsonis; Georgia Levidou; Helen A Papadaki; Panayiotis Panayiotidis; Maria K Angelopoulou
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

Review 10.  The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment.

Authors:  Claudia Pérez-Carretero; Isabel González-Gascón-Y-Marín; Ana E Rodríguez-Vicente; Miguel Quijada-Álamo; José-Ángel Hernández-Rivas; María Hernández-Sánchez; Jesús María Hernández-Rivas
Journal:  Diagnostics (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.